Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hospira

- PMLiVE

Novartis announces promising five-year data for leukaemia treatment Kymriah

Results have shown durable remission and long-term survival in children and young adults with B-cell acute lymphoblastic leukaemia

- PMLiVE

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Rheumatoid arthritis is a long-term condition that causes painful swelling and stiffness in the joints

- PMLiVE

Pfizer to expand Paxlovid manufacturing in US to meet global demand

The $120m investment will also create more than 250 high-skilled manufacturing jobs

- PMLiVE

Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

The initiative wants to increase the global use of biosimilars by at least 30% by 2030

- PMLiVE

Novartis’ Kymriah receives FDA approval to treat follicular lymphoma

The CAR-T cell treatment is approved for adult patients who have had two or more previous therapies

- PMLiVE

New Pfizer initiative, ‘An Accord for a Healthier World’, launched to improve global health equity

The company aims to provide support for 1.2 billion people in 45 lower-income countries

- PMLiVE

Pfizer to acquire Biohaven in deal worth over $11bn

The deal will expand Pfizer’s Internal Medicine pipeline

- PMLiVE

EC approves Novartis’ Kymriah for advanced blood cancer

Kymriah is the first CAR-T cell therapy of its kind approved in the EU for follicular lymphoma

- PMLiVE

Pfizer and Valneva announce positive phase 2 paediatric data for lyme disease vaccine

VLA15 is currently the only Lyme disease vaccine candidate in clinical development

- PMLiVE

Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara

The biosimilar was seen to have no clinically meaningful differences to Stelara

- PMLiVE

NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

Manufacturers will receive a fixed yearly fee of £10m, instead of receiving individual payments per dose

- PMLiVE

Pfizer appoints David Denton as chief financial officer and executive vice president

Denton’s appointment follows the departure of Frank D’Amelio, the current CFO and executive vice president

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links